相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Novel Proteasome Inhibitors to Overcome Bortezomib Resistance
Amy M. Ruschak et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Differences in Reversion of Resistance Mutations to Wild-Type under Structured Treatment Interruption and Related Increase in Replication Capacity
Agnes C. Paquet et al.
PLOS ONE (2011)
A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma
Dharminder Chauhan et al.
BLOOD (2010)
Immunoproteasomes Preserve Protein Homeostasis upon Interferon-Induced Oxidative Stress
Ulrike Seifert et al.
CELL (2010)
Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial
Maria-Victoria Mateos et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effect of Noncompetitive Proteasome Inhibition on Bortezomib Resistance
Xiaoming Li et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress
M. Ri et al.
LEUKEMIA (2010)
Bortezomib Retreatment in Relapsed Multiple Myeloma - Results from a Retrospective Multicentre Survey in Germany and Switzerland
I. Hrusovsky et al.
ONCOLOGY (2010)
Phase I Study of Bortezomib Combined With Chemotherapy in Children With Relapsed Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Therapeutic Advances in Childhood Leukemia (TACL) Consortium
Yoav Messinger et al.
PEDIATRIC BLOOD & CANCER (2010)
Resistance to Imatinib: Mutations and Beyond
Paul La Rosee et al.
SEMINARS IN HEMATOLOGY (2010)
Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome
Francesco Parlati et al.
BLOOD (2009)
Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line
Shuqing Lue et al.
EXPERIMENTAL HEMATOLOGY (2009)
The 26 S Proteasome: From Basic Mechanisms to Drug Targeting
Ami Navon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells
T. Rueckrich et al.
LEUKEMIA (2009)
Proteasome inhibitors in the treatment of multiple myeloma
J. J. Shah et al.
LEUKEMIA (2009)
A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis
Tony Muchamuel et al.
NATURE MEDICINE (2009)
Molecular basis of bortezomib resistance:: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein
Ruud Oerlemans et al.
BLOOD (2008)
Proteasome beta subunit pharmacogenomics: Gene resequencing and functional genomics
Liewei Wang et al.
CLINICAL CANCER RESEARCH (2008)
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
Jeffrey A. Engelman et al.
CLINICAL CANCER RESEARCH (2008)
Proteasome inhibitors in cancer therapy: Lessons from the first decade
Robert Z. Orlowski et al.
CLINICAL CANCER RESEARCH (2008)
Mechanisms of proteasome inhibitor action and resistance in cancer
David J. McConkey et al.
DRUG RESISTANCE UPDATES (2008)
Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line
Shuqing Lue et al.
EXPERIMENTAL HEMATOLOGY (2008)
Point mutation of the proteasome β5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line
Shuqing Lu et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome
Susan D. Demo et al.
CANCER RESEARCH (2007)
Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells
M. Kraus et al.
LEUKEMIA (2007)
20S proteasome and its inhibitors: Crystallographic knowledge for drug development
Ljudmila Borissenko et al.
CHEMICAL REVIEWS (2007)
Proteasome inhibition as novel treatment strategy in leukaemia
J. Vink et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
Esther A. Obeng et al.
BLOOD (2006)
Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132
Lisa J. A. Crawford et al.
CANCER RESEARCH (2006)
Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome
M Groll et al.
STRUCTURE (2006)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications
N Mitsiades et al.
BLOOD (2003)
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341
T Hideshima et al.
BLOOD (2003)
Molecular sequelae of proteasome inhibition in human multiple myeloma cells
N Mitsiades et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
The structure of the mammalian 20S proteasome at 2.75 Å resolution
M Unno et al.
STRUCTURE (2002)
Cells adapted to the proteasome inhibitor 4-hydroxy5-iodo-3-nitrophenylacetyl-Leu-Leu-leucinal-vinyl sulfone require enzymatically active proteasomes for continued survival
MF Princiotta et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Crystal structure of epoxomicin:20S proteasome reveals a molecular basis for selectivity of α′,β′-epoxyketone proteasome inhibitors
M Groll et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2000)
分享论文
